CompoAtlas

Gélules CBD "Sommeil" 750 mg

Food supplement declared in France

Gélules CBD "Sommeil" 750 mg (Novaloa) is a food supplement declared in France. Status: withdrawn from the market on 13 August 2026. Main ingredients: Hericium erinaceus 132.5 mg per day, Ganoderma lucidum(Curtis 132.5 mg per day, Withania somnifera 131.5 mg per day, Cannabis sativa 25 mg per day. 1 point in its composition requires a check (prohibited substance, dose or novel food).

Brand
Novaloa
Food business operator placing the product on the market
Nova CM Distribution
Status
Withdrawn from the market on 13 August 2026
Form
Capsule
Daily dose
1 gélule, soit 0,5 g de poudre
Directions for use
Gélules à avaler.
Intended populations
General population, Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Concurrent alcohol consumption, Liver problems, Taking antidepressants, Taking medication, Children (under 6), Children (under 10)
Objectives stated by the manufacturer (these are not authorised claims)
Autre : Sommeil

Declaration 260172, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Hericium erinaceusFruiting bodyDry aqueous extract132.5 mg
Ganoderma lucidum(Curtis ex Fr.) P.Karst.Fruiting bodyDry aqueous extract132.5 mg
Withania somnifera (L.) DunalRootDry alcoholic extract131.5 mg
Cannabis sativa L.Flowering topsSupercritical CO2 extract25 mg

Additives

E464

Other ingredients

huile de noix de coco fractionnée

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Consommation interdite aux mineurs et aux femmes enceintes et / ou allaitantes. En cas de problème hépatique, consommation fortement déconseillée. Prises d’alcool et / ou de médicaments concomitantes fortement déconseillées. Consulter un médecin en cas de doute.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Withania somnifera (L.) Dunal
    Read the warning, when it applies and the studies cited

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Sources cited by Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Health Canada monograph dated 28 February 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : Novaloa

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Gélules CBD "Sommeil" 750 mg (Novaloa): composition and regulation”, https://compoatlas.com/en/supplements/products/260172-gelules-cbd-sommeil-750-mg, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line